53104-32-8

Basic information

• Product Name: (5-AMINO-2,2-DIMETHYL-[1,3]DIOXAN-5-YL)-METHANOL
• Synonyms: AKOS 53;(5-AMINO-2,2-DIMETHYL-[1,3]DIOXAN-5-YL)-METHANOL;5-AMINO-2,2-DIMETHYL-1,3-DIOXANE-5-METHANOL;5-AMINO-2,2-DIMETHYL-1,3-DIOXANE-5-METH&
• CAS NO: 53104-32-8
• Molecular Formula: C₇H₁₅NO₃
• Molecular Weight: 161.2
• Product Categories: pharmacetical
• Mol File: 53104-32-8.mol
• Article Data: 25

Chemical Properties

• Melting Point: 55 °C
• Boiling Point: 241.5 °C at 760 mmHg
• Flash Point: 99.8 °C
• Appearance: /
• Density: 1.063g/cm³
• Vapor Pressure: 0.00617mmHg at 25°C
• Refractive Index: 1.449
• Storage Temp.: 2-8°C
• PKA: 14.58±0.10(Predicted)
• CAS DataBase Reference: (5-AMINO-2,2-DIMETHYL-[1,3]DIOXAN-5-YL)-METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (5-AMINO-2,2-DIMETHYL-[1,3]DIOXAN-5-YL)-METHANOL(53104-32-8)
• EPA Substance Registry System: (5-AMINO-2,2-DIMETHYL-[1,3]DIOXAN-5-YL)-METHANOL(53104-32-8)

Safety Data

• Hazardous Substances Data: 53104-32-8(Hazardous Substances Data)

Usage

General Description

(5-amino-2,2-dimethyl-[1,3]dioxan-5-yl)-methanol is a chemical compound with the molecular formula C7H15NO3. It is a derivative of dioxane, a six-membered heterocyclic chemical compound with the molecular formula C4H8O2. (5-AMINO-2,2-DIMETHYL-[1,3]DIOXAN-5-YL)-METHANOL contains an amino group, a methyl group, and a hydroxyl group, making it a versatile building block for organic synthesis. It can be used as a building block for the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. The presence of the amino group makes it a potentially useful compound for the development of new drugs or materials with specific biological or chemical properties.

InChI:InChI=1/C7H15NO3/c1-6(2)10-4-7(8,3-9)5-11-6/h9H,3-5,8H2,1-2H3

Upstream product

• 77-76-9 2,2-dimethoxy-propane 
• 77-86-1 2-amino-2-hydroxymethyl-1,3-propanediol 
• 104-15-4 toluene-4-sulfonic acid 
• 1185-53-1 tris hydrochloride 
• 4728-14-7 2,2-dimethyl-5-hydroxymethyl-5-nitro-1,3-dioxane 

Relevant articles and documents

Structural development of p-carborane-based potent non-secosteroidal vitamin D analogs

Non-secosteroidal vitamin D receptor (VDR) ligands are promising candidates for many clinical applications. We recently developed novel non-secosteroidal VDR agonists based on p-carborane (an icosahedral carbon-containing boron cluster) as a hydrophobic c

Glycodendrimersomes from Sequence-Defined Janus Glycodendrimers Reveal High Activity and Sensor Capacity for the Agglutination by Natural Variants of Human Lectins

A library of eight amphiphilic Janus glycodendrimers (Janus-GDs) presenting d-lactose (Lac) and a combination of Lac with up to eight methoxytriethoxy (3EO) units in a sequence-defined arrangement was synthesized via an iterative modular methodology. The length of the linker between Lac and the hydrophobic part of the Janus-GDs was also varied. Self-assembly by injection from THF solution into phosphate-buffered saline led to unilamellar, monodisperse glycodendrimersomes (GDSs) with dimensions predicted by Janus-GD concentration. These GDSs provided a toolbox to measure bioactivity profiles in agglutination assays with sugar-binding proteins (lectins). Three naturally occurring forms of the human adhesion/growth-regulatory lectin galectin-8, Gal-8S and Gal-8L, which differ by the length of linker connecting their two active domains, and a single amino acid mutant (F19Y), were used as probes to study activity and sensor capacity. Unpredictably, the sequence of Lac on the Janus-GDs was demonstrated to determine bioactivity, with the highest level revealed for a Janus-GD with six 3EO groups and one Lac. A further increase in Lac density was invariably accompanied by a substantial decrease in agglutination, whereas a decrease in Lac density resulted in similar or lower bioactivity and sensor capacity. Both changes in topology of Lac presentation of the GDSs and seemingly subtle alterations in protein structure resulted in different levels of bioactivity, demonstrating the presence of regulation on both GDS surface and lectin. These results illustrate the applicability of Janus-GDs to dissect structure-activity relationships between programmable cell surface models and human lectins in a highly sensitive and physiologically relevant manner.

A Condensed, Scalable Synthesis of Racemic Koningic Acid

The natural product koningic acid (KA) is a selective covalent inhibitor of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a critical node in the glycolysis pathway. While KA is available commercially, sources are limited and its cost becomes rapidly prohibitive beyond the milligram scale. Additionally, a practical and flexible synthetic route to KA and analogs remains to be developed. Here we detail a new route that is operationally safer, scalable and offers a five-step reduction in the previously reported longest linear sequence.

Novel lipid-mimetic prodrugs delivering active compounds to adipose tissue

Obesity and associated pathologies are a dramatically growing problem. New therapies to prevent and/or cure them are strongly needed. Adipose tissue is a logical target for pharmacological intervention, since it is now recognized to exert an important endocrine function, secreting a variety of adipokines affecting, for example, adiposity and insulin resistance. This proof of principle work focuses on the development of novel lipid-mimetic prodrugs reaching fat deposits by the same lymphatic absorption route followed by dietary triglycerides. Pterostilbene, a natural phenolic compound with potential anti-obesity effects, was used as model “cargo”, attached via a carbamate group to an ω-aminodecanoate chain linked to either position 1 or position 2 of the glycerol moiety of synthetic triglycerides. The prodrugs underwent position-selective hydrolysis when challenged with pancreatic lipases in vitro. Pterostilbene-containing triglycerides as well as pterostilbene and its metabolites were present in the adipose tissue of mice fed an obesogenic diet containing one or the other of the derivatives. For the first time this approach is used to deliver an obesity antagonist to the adipose tissue. The results demonstrate the feasibility of delivering active compounds to adipose tissue by reversibly incorporating them into triglyceride-mimetic structures. Upon release in the target site these compounds are expected to exert their pharmacological activity precisely where needed.